Axitinib is a selective inhibitor of VEGF receptors 1, 2 and 3 that blocks tumour angiogenesis, used for the treatment of advanced renal cell carcinoma. Simson Pharma's Axitinib reference standard and impurities support stability-indicating method development for this antiangiogenic oncology agent.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Axitinib Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.